Premium
Transcatheter closure of perimembranous ventricular septal defects using the amplatzer membranous VSD occluder: Immediate and midterm results of an international registry
Author(s) -
Holzer Ralf,
de Giovanni Jo,
Walsh Kevin P.,
Tometzki Andrew,
Goh TH,
Hakim Fakhri,
Zabal Carlos,
de Lezo Jose Suarez,
Cao QiLing,
Hijazi Ziyad M.
Publication year - 2006
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.20659
Subject(s) - medicine , ventricular outflow tract , fluoroscopy , regurgitation (circulation) , cardiology , atrioventricular block , heart block , cardiac skeleton , ventricle , surgery , percutaneous , cardiac catheterization , electrocardiography , aortic valve replacement , stenosis
Objective : To report the immediate and midterm results of transcatheter closure of perimembranous ventricular septal defect (PmVSD) using the Amplatzer membranous VSD occluder (AMVSD). Methods : Between April 2002 and August 2004, 100 patients underwent an attempt of percutaneous device closure of PmVSD using the AMVSD in 24 international centers. The median age was 9.0 years (0.7–58 years) and the median weight was 27.5 kg (7–121 kg). Results : A device was successfully deployed in 93/100 (93%) patients. Reasons for procedural failure were an increased gradient across the left ventricle outflow tract in one patient, aortic regurgitation in 2 patients, and inability to securely position the device in 4 patients. The median VSD size by TEE was 7.0 mm (1.5–13 mm), median device size 10 mm (4–16 mm) and median fluoroscopy time 22.1 min (8.9–96.0 min). Weight below 10 kg ( P = 0.0392), inlet extension of the VSD ( P = 0.0139) and aortic cusp prolapse into the VSD ( P = 0.0084) were significantly associated with a lower procedural success. Patients have been followed up for a median of 182 days (1–763 days). There were no procedure‐related deaths. Complications were encountered in 29/100 (29%) patients, including rhythm or conduction anomalies in 13 patients (two with complete heart block requiring permanent pacemaker implantation), new or increased aortic (9 patients) or tricuspid (9 patients) regurgitation, most of which were classified as trivial or mild. Patients with a weight below 10 kg had a significantly higher incidence of adverse events than patients with a weight above 10 kg (58.3% versus 25.0%, P = 0.0285). Immediately after device release complete closure of the defect was present in 54/93 (58.1%) patients, increasing to 46/55 (83.6%) patients at 6‐months follow‐up ( P = 0.0012). Left ventricle end‐diastolic diameter decreased from a median of 44 mm prior to device closure to a median of 39 mm at 6‐months postprocedure ( P = 0.0015). Conclusion : Closure of PmVSDs using the AMVSD occluder is safe and effective. However, longer follow‐up period is warranted prior to the wide spread use of this device. © 2006 Wiley‐Liss, Inc.